General Ophthalmology

49-64 of 381

Macular Leakage: Indicator of Vascular Stability
Macular Leakage: Indicator of Vascular Stability
MinuteCE®
Macular Leakage: Indicator of Vascular Stability
Justis P. Ehlers, MD, FASRS; Jennifer, I. Lim, MD, FASRS, FARVO
1.00 program credit
- Justis P. Ehlers, MD, FASRS
- Jennifer, I. Lim, MD, FASRS, FARVO
1.00 program credit
Predicting Durability: Where Are We Now?
Predicting Durability: Where Are We Now?
MinuteCE®
Predicting Durability: Where Are We Now?
Justis P. Ehlers, MD, FASRS; Jennifer, I. Lim, MD, FASRS, FARVO
1.00 program credit
- Justis P. Ehlers, MD, FASRS
- Jennifer, I. Lim, MD, FASRS, FARVO
1.00 program credit
Signs of Progress: PED as a Predictor of Disease and Outcomes
Signs of Progress: PED as a Predictor of Disease and Outcomes
MinuteCE®
Signs of Progress: PED as a Predictor of Disease and Outcomes
Justis P. Ehlers, MD, FASRS; Jennifer, I. Lim, MD, FASRS, FARVO
1.00 program credit
- Justis P. Ehlers, MD, FASRS
- Jennifer, I. Lim, MD, FASRS, FARVO
1.00 program credit
Fluid Foundations: How Location Impacts Outcomes in nAMD
Fluid Foundations: How Location Impacts Outcomes in nAMD
MinuteCE®
Fluid Foundations: How Location Impacts Outcomes in nAMD
Roger A. Goldberg, MD, MBA; Ehsan Rahimy, MD
1.00 program credit
- Roger A. Goldberg, MD, MBA
- Ehsan Rahimy, MD
1.00 program credit
Fluid Dynamics Demystified
Fluid Dynamics Demystified
MinuteCE®
Fluid Dynamics Demystified
Roger A. Goldberg, MD, MBA; Ehsan Rahimy, MD
1.00 program credit
- Roger A. Goldberg, MD, MBA
- Ehsan Rahimy, MD
1.00 program credit
Real-World Adaptation of Trial Protocols
Real-World Adaptation of Trial Protocols
MinuteCE®
Real-World Adaptation of Trial Protocols
Roger A. Goldberg, MD, MBA; Ehsan Rahimy, MD
1.00 program credit
- Roger A. Goldberg, MD, MBA
- Ehsan Rahimy, MD
1.00 program credit
The Durability Dilemma
The Durability Dilemma
MinuteCE®
The Durability Dilemma
Roger A. Goldberg, MD, MBA; Ehsan Rahimy, MD
1.00 program credit
- Roger A. Goldberg, MD, MBA
- Ehsan Rahimy, MD
1.00 program credit
Early Fluid Resolution – A Key to Long-Term Success
Early Fluid Resolution – A Key to Long-Term Success
MinuteCE®
Early Fluid Resolution – A Key to Long-Term Success
Roger A. Goldberg, MD, MBA; Ehsan Rahimy, MD
1.00 program credit
- Roger A. Goldberg, MD, MBA
- Ehsan Rahimy, MD
1.00 program credit
Eye on the Target: Navigating Ocular Challenges With ADC Cancer Therapies
Eye on the Target: Navigating Ocular Challenges With ADC Cancer Therapies
CME/CE Broadcast Replay
Eye on the Target: Navigating Ocular Challenges With ADC Cancer Therapies
Kathleen N. Moore, MD, MS, FASCO; Aaron Samuel Gold, OD, FAAO
1.00 credit
- Kathleen N. Moore, MD, MS, FASCO
- Aaron Samuel Gold, OD, FAAO
- Carlo J. Pelino, OD, FAAO
1.00 credit
Leveling Access in Retinal Care: Driving Equity with Innovative Therapies
Leveling Access in Retinal Care: Driving Equity with Innovative Therapies
CME/CE Broadcast Replay
Leveling Access in Retinal Care: Driving Equity with Innovative Therapies
Jennifer, I. Lim, MD, FASRS, FARVO; Jeremiah Brown Jr., MD, MS, FASRS
1.00 credit
- Jennifer, I. Lim, MD, FASRS, FARVO
- Jeremiah Brown Jr., MD, MS, FASRS
- Rahul N. Khurana, MD, FASRS
1.00 credit
Antibody Drug Conjugates: Pretreatment Assessment and Ocular Toxicity Awareness
Antibody Drug Conjugates: Pretreatment Assessment and Ocular Toxicity Awareness
CME/CE
Antibody Drug Conjugates: Pretreatment Assessment and Ocular Toxicity Awareness
Kathleen N. Moore, MD, MS, FASCO; Kamran M. Riaz, MD
0.25 credits
- Kathleen N. Moore, MD, MS, FASCO
- Kamran M. Riaz, MD
0.25 credits
Collaborative Care: Managing ADC-Related Ocular Toxicities
Collaborative Care: Managing ADC-Related Ocular Toxicities
CME/CE
Collaborative Care: Managing ADC-Related Ocular Toxicities
Kathleen N. Moore, MD, MS, FASCO; Carlo J. Pelino, OD, FAAO
0.25 credits
- Kathleen N. Moore, MD, MS, FASCO
- Carlo J. Pelino, OD, FAAO
0.25 credits
Understanding Antibody-Drug Conjugates (ADCs)
Understanding Antibody-Drug Conjugates (ADCs)
CME/CE
Understanding Antibody-Drug Conjugates (ADCs)
Aaron Samuel Gold, OD, FAAO; Carlo J. Pelino, OD, FAAO
0.25 credits
- Aaron Samuel Gold, OD, FAAO
- Carlo J. Pelino, OD, FAAO
0.25 credits
Antibody Drug Conjugates: Insights and Challenges in Oncology and Ophthalmology
Antibody Drug Conjugates: Insights and Challenges in Oncology and Ophthalmology
CME/CE
Antibody Drug Conjugates: Insights and Challenges in Oncology and Ophthalmology
Aaron Samuel Gold, OD, FAAO; Timothy G. Murray, MD, MBA, FASRS
0.25 credits
- Aaron Samuel Gold, OD, FAAO
- Timothy G. Murray, MD, MBA, FASRS
0.25 credits
Charting GA Progression: From Early Signs to Treatment Strategies
Charting GA Progression: From Early Signs to Treatment Strategies
CME/CE Broadcast Replay
Charting GA Progression: From Early Signs to Treatment Strategies
Roger A. Goldberg, MD, MBA
1.00 credit
- Roger A. Goldberg, MD, MBA
1.00 credit
KOL KNOCKOUT™ MEDICAL RETINA EDITION
Vying for Superior Patient Outcomes in Retinal Care
KOL KNOCKOUT™ MEDICAL RETINA EDITION
Vying for Superior Patient Outcomes in Retinal Care
CME/CE
KOL KNOCKOUT™ MEDICAL RETINA EDITION
Vying for Superior Patient Outcomes in Retinal Care
Sunil K. Srivastava, MD; Sruthi Arepalli, MD
1.50 credits
- Sunil K. Srivastava, MD
- Sruthi Arepalli, MD
- Durga Borkar, MD, MMCi
- Hong-Uyen Hua, MD
- Abdul-Hadi Kaakour, MD, MS
- Ananth Sastry, MD
1.50 credits

4/9